OBJECTIVE: The matrix metalloproteinases (MMPs) have been implicated in the aggressive course of non-small cell lung cancer (NSCLC). However, there are a large number of MMP subtypes with diverse proteolytic substrates and different induction pathways. This study tested the hypothesis that a differential MMP profile would exist between NSCLC and normal lung and that MMP patterns would differ between NSCLC histologic types. METHODS: NSCLC samples and remote normal samples were obtained from patients with stage I or II NSCLC with either squamous cell (n = 22) or adenocarcinoma (n = 19) histologic characteristics. Absolute concentrations for each of the MMP subclasses were determined by a calibrated and validated multiplex suspension array: collagenases (MMP-1, -8, and -13), gelatinases (MMP-2 and -9), lysins (MMP-2 and -7), and elastase (MMP-12). RESULTS: Overall, MMP levels were significantly increased in NSCLC compared with normal. For example, MMP-1 and MMP-7 increased by approximately 10-fold in NSCLC (P < .05). Moreover, a different MMP portfolio was observed between NSCLC histologic types. For example MMP-1, -8, -9, and -12 increased by more than 4-fold in squamous cell versus adenocarcinoma (P < .05). In those patients who had recurrence within 3 years of resection, 3-fold higher levels of MMP-8 and -9 were observed (P < .05). CONCLUSION: Increased levels of a number of MMP types occur with NSCLC, but the MMP profile was distinctly different between histologic types and in those patients with recurrence. These different MMP profiles may be important in the mechanistic basis for the natural history of different NSCLC types, as well as identifying potential prognostic and therapeutic targets. Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
OBJECTIVE: The matrix metalloproteinases (MMPs) have been implicated in the aggressive course of non-small cell lung cancer (NSCLC). However, there are a large number of MMP subtypes with diverse proteolytic substrates and different induction pathways. This study tested the hypothesis that a differential MMP profile would exist between NSCLC and normal lung and that MMP patterns would differ between NSCLC histologic types. METHODS:NSCLC samples and remote normal samples were obtained from patients with stage I or II NSCLC with either squamous cell (n = 22) or adenocarcinoma (n = 19) histologic characteristics. Absolute concentrations for each of the MMP subclasses were determined by a calibrated and validated multiplex suspension array: collagenases (MMP-1, -8, and -13), gelatinases (MMP-2 and -9), lysins (MMP-2 and -7), and elastase (MMP-12). RESULTS: Overall, MMP levels were significantly increased in NSCLC compared with normal. For example, MMP-1 and MMP-7 increased by approximately 10-fold in NSCLC (P < .05). Moreover, a different MMP portfolio was observed between NSCLC histologic types. For example MMP-1, -8, -9, and -12 increased by more than 4-fold in squamous cell versus adenocarcinoma (P < .05). In those patients who had recurrence within 3 years of resection, 3-fold higher levels of MMP-8 and -9 were observed (P < .05). CONCLUSION: Increased levels of a number of MMP types occur with NSCLC, but the MMP profile was distinctly different between histologic types and in those patients with recurrence. These different MMP profiles may be important in the mechanistic basis for the natural history of different NSCLC types, as well as identifying potential prognostic and therapeutic targets. Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
Authors: Rebecca Suk Heist; Ariela L Marshall; Geoffrey Liu; Wei Zhou; Li Su; Donna Neuberg; Thomas J Lynch; John Wain; David C Christiani Journal: Clin Cancer Res Date: 2006-09-15 Impact factor: 12.531
Authors: Rachael L Ford; Ira M Mains; Ebony J Hilton; Scott T Reeves; Robert E Stroud; Fred A Crawford; John S Ikonomidis; Francis G Spinale Journal: Ann Thorac Surg Date: 2008-11 Impact factor: 4.330
Authors: Azizbek Ramankulov; Michael Lein; Manfred Johannsen; Mark Schrader; Kurt Miller; Klaus Jung Journal: Cancer Sci Date: 2008-04-14 Impact factor: 6.716
Authors: Bernhard Gentner; Axel Wein; Roland S Croner; Isabel Zeittraeger; Ralph M Wirtz; Franz Roedel; Arno Dimmler; Laure Dorlaque; Werner Hohenberger; Eckhart G Hahn; Wolfgang M Brueckl Journal: Anticancer Res Date: 2009-01 Impact factor: 2.480
Authors: Julia S Pettersen; Judilyn Fuentes-Duculan; Mayte Suárez-Fariñas; Katherine C Pierson; Alexander Pitts-Kiefer; Linda Fan; Daniel A Belkin; Claire Q F Wang; Shivaprasad Bhuvanendran; Leanne M Johnson-Huang; Mark J Bluth; James G Krueger; Michelle A Lowes; John A Carucci Journal: J Invest Dermatol Date: 2011-02-10 Impact factor: 8.551
Authors: Wei Yu; Li Chen; Yu-Qing Yang; John R Falck; Austin M Guo; Ying Li; Jing Yang Journal: Cancer Chemother Pharmacol Date: 2010-12-01 Impact factor: 3.333
Authors: Kathleen L Decicco-Skinner; Sarah A Jung; Tracy Tabib; J Curtis Gwilliam; Hepzibha Alexander; Sarah E Goodheart; Anand S Merchant; Mengge Shan; Caroline Garber; Jonathan S Wiest Journal: Carcinogenesis Date: 2013-09-25 Impact factor: 4.944
Authors: Michael R Mehan; Deborah Ayers; Derek Thirstrup; Wei Xiong; Rachel M Ostroff; Edward N Brody; Jeffrey J Walker; Larry Gold; Thale C Jarvis; Nebojsa Janjic; Geoffrey S Baird; Sheri K Wilcox Journal: PLoS One Date: 2012-04-11 Impact factor: 3.240